⌘K
Loading ticker…
As of 2026-08-24, Milestone Pharmaceuticals Inc. Common Shares (MIST) has a 3-month relative strength percentile of 16 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 36. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.0%, relative volume 0.86×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MIST is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -13.8% / -38.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MIST appears in 1 ETF as of May 2026: QQQS at 0.34% weight, $64K notional.
Held by 3 ETFs · $2M across latest filings · largest weight 2.58% (SURI).
Top 1 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| QQQS | 0.34% | $64K | +0.04 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MIST Jan avg: -8.43% median: -6.51% win: 0% σ: 5.57% n: 4 2022-04-12 → 2026-07-31 | MIST Feb avg: -9.10% median: -12.07% win: 25% σ: 9.80% n: 4 2022-04-12 → 2026-07-31 | MIST Mar avg: -12.52% median: -11.93% win: 50% σ: 34.36% n: 4 2022-04-12 → 2026-07-31 | MIST Apr avg: 19.30% median: -4.04% win: 40% σ: 35.80% n: 5 2022-04-12 → 2026-07-31 | MIST May avg: -2.92% median: -9.09% win: 40% σ: 18.16% n: 5 2022-04-12 → 2026-07-31 | MIST Jun avg: -3.18% median: -5.63% win: 40% σ: 18.53% n: 5 2022-04-12 → 2026-07-31 | MIST Jul avg: 0.23% median: 9.09% win: 60% σ: 20.25% n: 5 2022-04-12 → 2026-07-31 | MIST Aug avg: 6.18% median: 7.43% win: 50% σ: 19.38% n: 4 2022-04-12 → 2026-07-31 (current) | MIST Sep avg: 9.38% median: 7.87% win: 100% σ: 4.33% n: 4 2022-04-12 → 2026-07-31 | MIST Oct avg: -17.85% median: -11.01% win: 0% σ: 19.37% n: 4 2022-04-12 → 2026-07-31 | MIST Nov avg: 26.41% median: 33.86% win: 75% σ: 19.49% n: 4 2022-04-12 → 2026-07-31 | MIST Dec avg: -18.92% median: -22.13% win: 25% σ: 28.34% n: 4 2022-04-12 → 2026-07-31 |